



MedAdvisor Limited
ACN 145 327 617
Level 2, 971 Burke Road
Camberwell Vic 3124
mymedadvisor.com/investors

MARKET RELEASE

MedAdvisor to repay Syneos convertible notes

Melbourne, Australia, 22 March, 2021 - Medtech company, MedAdvisor Limited (ASX: MDR) (**MedAdvisor**) announces that Syneos Health US, Inc. (**Syneos**) has elected not to convert the convertible notes issued as deferred consideration for MedAdvisor's acquisition of Adheris, LLC in November 2020.

In accordance with the Convertible Note Agreement, MedAdvisor will repay Syneos approximately USD \$5.03m (being the face value and accrued interest) on 17 May 2021. This payment can be funded from existing cash reserves.

MedAdvisor has been pleased with the acquisition of Adheris which beat H1 investment case forecasts by 40% delivering revenue of USD\$19.3m (vs. \$13.8m investment case). The sales pipeline continues to build, and the integration is progressing well. With ~80% of MedAdvisor's revenue coming from the US and a US customer base, MedAdvisor has begun increasing investor relations efforts in the US following recent inbound interest from investors, as part of a strategy to ensure the company has appropriate investor coverage in its key markets.

- ENDS -

This document has been authorised for release by Naomi Lawrie, MedAdvisor Company Secretary.

For more information:

Simon Glover
Chief Financial Officer
corporate@medadvisor.com.au
+61 3 9095 3036

Alex Beashel
Corporate Communications
ab@alexbeashel.com
+61 466 308 667

About MedAdvisor

MedAdvisor is a world-class medication management platform that empowers users to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects users to tools and education materials from their local/preferred pharmacy. In Australia, MedAdvisor has connected over 1.6 million users through more than 60% of Australian pharmacies and a network of thousands of GPs. MedAdvisor has recently partnered with HMS in the US, Zuellig Pharma in Asia and launched into the UK on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: mymedadvisor.com/investors